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TO THE EDITOR
Chymase has been thought to play an
important role in the pathogenesis of
atopic dermatitis; for example, (i) an
intradermal injection of chymase to
mouse skin elicits edema as well as
inflammatory cell accumulation (Tomi-
mori et al., 2002a, c), (ii) there are
several reports suggesting a correlation
between a certain single-nucleotide
polymorphism of the chymase gene
and incidence of atopic dermatitis
(Mao et al., 1996; Tanaka et al., 1999;
Weidinger et al., 2005). In fact, a
chymase inhibitor SUN C8257 has
been shown to improve dermatitis in
several animal models (Tomimori et al.,
2002a, c; Watanabe et al., 2002).
However, the effect of the compound
was shown exclusively when adminis-
tered intraperitoneally (Tomimori et al.,
2002a, c) or given as drinking water
(Watanabe et al., 2002), as this com-
pound has a very low bioavailability
and short half-life in vivo. Recently, we
have synthesized a novel chymase
inhibitor with an improved profile,
SUN13350 (free form of SUN13834).
(Hiroshi Maruoka, Tsuyoshi Muto,
Taisaku Tanaka, Seiichi Imajo, Yoshiaki
Tomimori, Yoshiaki Fukuda, and
Takashi Nakatsuka: development of
6-benzyl substituted 4-aminocarbonyl-
1,4-diazepane-2,5-diones as orally
active human chymase inhibitors,
manuscript in preparation). In this
letter, we report the effect of
SUN13350 on NC/Nga mice which
spontaneously develop dermatitis in
conventional (nonspecific pathogen-
free) conditions (Matsuda et al., 1997).
To examine the effect of SUN13350
on NC/Nga mice, the compound was
administered orally once a day for
3 weeks, starting at 8 weeks old (the
medical ethical committee of The Jikei
University approved all described stu-
dies). As shown in Figure 1a, the clinical
scores increased in the control mice
with aging and were reduced signifi-
cantly and completely by the treatment
with SUN13350 at 30 mg/kg. The
effect of SUN13350 was obvious by
macroscopic observation (the photo of
the representative mice is shown in
Figure 1b). Histological analysis of
the skin revealed that administration
of SUN13350 significantly inhibited
the number of mast cells and eosino-
phils (Figure 1c and d) compared
to control mice. In addition, administra-
tion of SUN13350 at 30 mg/kg signifi-
cantly reduced the serum level of
IgE compared to the control mice
(Figure 1e).
Chymase is known to participate in
mast cell accumulation by releasing
soluble stem cell factor (SCF) from
membrane-bound SCF (Longley et al.,
1997; Tomimori et al., 2002b). To
understand the mechanism of inhibition
of mast cell accumulation in NC/Nga
mice, the effect of SUN13350 was
examined on the chymase-induced
processing of SCF in vitro. Recombinant
human SCF with 165 amino-acid resi-
dues (SCF165) was detected as a single
and sharp band with an apparent
molecular weight of approximately
21 kDa in SDS-PAGE (Figure 2a). In-
cubation of human SCF165 with human
chymase resulted in the production of a
shorter species (B20 kDa) of the pro-
tein, consistent with the data of the
previous report of Longley et al. (1997),
who showed that chymase cleaves
membrane-bound SCF at a site close
to the membrane to yield a soluble
bioactive form. SUN13350 inhibited
the production of the shorter species
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Figure 1. Effect of SUN13350 on NC/Nga mice. SUN13350 was administered to NC/Nga mice orally
once a day for 3 weeks at 30 mg/kg, starting at 8 weeks old. (a) The clinical skin scores were determined
by the criteria (see Materials in Supplementary Materials) at 2 and 3 weeks after the first administration
(closed square, control mice; open triangle, SUN13350-treated mice). The photo of the representative
mice (11 weeks old) was shown in (b). Skin samples of the back of the mice were taken at the end of the
experiment (at 3 weeks after the first administration) and the numbers of (c) mast cells and (d) eosinophils
were counted. The concentration of (e) IgE in the serum was measured at 3 weeks after the first
administration. Data are mean7SD (N¼ 4–5). *Po0.05; **Po0.01 as compared with control group
(a) Mann–Whitney U-test and (c–e) Student’s t-test.
Abbreviation: SCF, stem cell factor
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of SCF (Figure 2a), with a complete
inhibition at more than 0.5mM. This
result demonstrates that SUN13350
inhibits the chymase-induced proces-
sing of membrane-bound SCF. Similar
results were obtained using mouse
recombinant SCF164 and mouse chy-
mase mMCP-4 (mouse mast cell pro-
tease-4), whereas SUN13350 at 0.5mM
showed partial effects (Figure 2a). These
data suggest that the reduction of mast
cell accumulation in NC/Nga mice by
SUN13350 may be mediated by inhibi-
tion of the release of soluble SCF.
Chymase is also known as a chemo-
attractant for various inflammatory cells
including eosinophils (He and Walls,
1998; Tani et al., 2000). Therefore, the
effect of SUN13350 on chymase-in-
duced eosinophil migration was exam-
ined by chemotaxis analysis in vitro. As
shown in Figure 2b, human chymase
induced migration of human eosino-
phils, in agreement with the previous
report (Tani et al., 2000). SUN13350
significantly inhibited the chymase-in-
duced cell migration at more than
1.0 mM, and complete inhibition was
observed at 100 mM. Similarly, mouse
chymase mMCP-4 induced migration of
mouse eosinophils isolated from peri-
tonitis mice, and SUN13350 inhibited
mMCP-4-induced chemotaxis (Figure
2c). These results suggest that eosino-
phil infiltration to the skin observed in
NC/Nga mice may be mediated at least
in part by chymase, and that the
inhibition of eosinophil accumulation
by SUN13350 may be due to the
inhibition of chymase-induced eosino-
phil migration.
Administration of SUN13350 reduced
the serum level of IgE in NC/Nga mice
(Figure 1e), which may be the result of
the improvement of the dermatitis.
However, chymase is known to stimu-
late IgE production from mouse B
cells in vitro (Yoshikawa et al., 2001).
Thus it is also possible that SUN13350
inhibits IgE production in NC/Nga
mice as well and in turn ameliorates
dermatitis.
In conclusion, it was shown that a
novel chymase inhibitor SUN13350
ameliorates dermatitis in NC/Nga mice
when administered orally, and that
inhibition of SCF-processing and eosi-
nophil infiltration might be involved in
the effect of the compound. Most of the
existing therapies for atopic dermatitis
(such as corticosteroids and immuno-
suppressants) are ointments or creams,
as they exert adverse effects when
administered systemically. SUN13350
was shown to inhibit the processing of
human SCF as well as chemotaxis of
human eosinophils, and therefore is
thought to be promising as a novel oral
agent for human atopic dermatitis.
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Figure 2. Effect of SUN13350 on chymase-induced digestion of SCF and eosinophil chemotaxis.
(a) Human SCF165 and mouse SCF164 was incubated with human chymase and mouse chymase mMCP-4,
respectively, in the presence or absence of various concentrations of SUN13350 at 371C for 10 minutes.
The digestion of SCF by chymase was then examined by SDS-PAGE analysis using 15–25% gel.
The apparent molecular weights of the intact and digested SCF shown on the left were determined
(see Materials and Methods in Supplementary Materials). (b and c) The bands for human chymase and
mMCP-4 were also identified by the same method. (b) Human eosinophils and (c) mouse eosinophils
were isolated from human peripheral blood and peritoneal fluid of the peritonitis mice, respectively and
chemotaxis analysis was performed (see Materials and Methods in Supplementary Materials). Data are
expressed as migrated cells per high-power field (mean7SD). Hatched bar, chymase; Closed bar, control
(without chymase); n¼ 3–4; #Po0.01 compared with the control (Student’s t-test); **Po0.01 compared
with the wells containing chymase but not any inhibitor (Dunnett’s test).
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Atopic Skin Is Associated with a Lack of
Phosphatidylcholine–Sphingomyelin Transacylase Activity
Journal of Investigative Dermatology (2007) 127, 973–975. doi:10.1038/sj.jid.5700623; published online 9 November 2006
TO THE EDITOR
The clinical phenotype of atopic der-
matitis (AD) results from complex inter-
actions of individual susceptibility and
environmental factors, and of the state
of immune responses. An impaired
barrier function of the epidermis is
more and more seen as a predisposing
factor for AD development rather than
as a consequence (Bos et al., 1994;
Jensen et al., 2004; Palmer et al., 2006;
see for a review, Proksch et al., 2003).
An intact stratum corneum assembled
by corneocytes and extracellular lipids
helps to prevent the sensitizing aller-
gens from entering. Heritable defects
giving rise to abnormal cornification
and to alterations in lipid composition
increase the opportunity of immuno-
logically active environmental substances
to contact and to activate antigen-
presenting cells that are required to
provoke the eczematous skin lesions.
The amount of total stratum cor-
neum lipids is consistently decreased in
AD patients, but particularly changes in
content and composition of ceramides
are suspected to facilitate transepider-
mal allergen transfer (see for a review,
Proksch et al., 2003). The actual local
ceramide content is determined by a
network of forming and degrading
activities. Ceramide levels in AD were
found to be reduced by impaired
sphingomyelinase activities (Jensen
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Figure 1. Atopic skin specimens lack PC–SM transacylase activity. Fluorescence-labelled C5-PC was
added to whole epidermal cell homogenates of normal and of AD skin specimens, and reactions
proceeded for 15 minutes. A typical HPTLC plate is shown. State of AD: subacute (1), acute (2, 3), and
chronic (4, 5) (Cer, ceramide; FA, fatty acid; PC, phosphatidylcholine; SM, sphingomyelin). Whole-cell
homogenates of healthy skin specimen and of clinically and histologically diagnosed AD skin biopsies
from affected sites were obtained by treatment with dispase I and trypsin followed by sonication in 50 mM
3-[N-morpholino]propane sulfonic acid (pH 7.4), 1 mM EDTA, 1 protease inhibitor cocktail (Roche,
Mannheim, Germany). Protein concentrations were determined by using a Micro BCA protein assay kit
(Pierce, Rockford, IL). For assays of enzymatic activities, fluorescent lipids at final concentrations of 5mM
were injected into a stirring solution of 50 mM 3-[N-morpholino]propane sulfonic acid (pH 7.4), 5mM fatty-
acid-free bovine albumin (Sigma, Deisenhofen, Germany). For SMase assay, 5 mM MgCl2, for SM deacylase
assay 2.5 mM CaCl2, and for SM synthase 20 mM EDTA was present. Fluorescent BODIPY FL lipids were:
C5-SM, 1,2-bis C11-PC (both of the acyl-chains labelled), C5-HPC (acyl-chain in C2-position labelled),
C5-cer (Molecular Probes, Leiden, The Netherlands). Homogenates were added at final cellular protein
concentrations of 0.2 mg/ml. HPTLC was performed on silica-gel 60 glass plates (Merck, Darmstadt,
Germany). Mobile phase: chloroform:methanol:H2O¼55:20:3 (v:v:v). Standards were commercially
available BODIPY FL lipids as well as lipids prepared thereof (Molecular Probes; Wanner et al., 2004).
Abbreviation: AD, atopic dermatitis; PC, phosphatidylcholine; SM, sphingomyelin
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